Content with topic

Nonpharmacologic approaches to promote population cardiovascular health
Salim Yusuf
May 25, 2022 | 90th EAS Congress 2022, Plenary 3: From lifestyle to designer therapies | #
Should we target inflammation?
Paul Ridker
May 25, 2022 | 90th EAS Congress 2022, Plenary 3: From lifestyle to designer therapies | #
Artificial Intelligence assisted diagnostics of atherosclerotic vascular disease
Charalambos Antoniades
May 25, 2022 | 90th EAS Congress 2022, Plenary 3: From lifestyle to designer therapies | #
Genome-wide regulation of microRNAs in endothelial cells
Minna Kaikkonen-Määttä
May 24, 2022 | 90th EAS Congress 2022, Endothelial cell biology in atherosclerosis | #
Role of protrudin in endothelial cell function
Amita Arora
May 24, 2022 | 90th EAS Congress 2022, Endothelial cell biology in atherosclerosis | #
Endothelial TKK1 deficiency reduces eNOS MRNA levels, promoting endothelial dysfunction and atherogenesis
Goo Taeg Oh
May 24, 2022 | 90th EAS Congress 2022, Endothelial cell biology in atherosclerosis | #
Endothelial cannabinoid receptor CB1 deficiency decreases OxLDL uptake and attenuates vascular inflammation in atherosclerosis
Bingni Chen
May 24, 2022 | 90th EAS Congress 2022, Endothelial cell biology in atherosclerosis | #
Endothelial ACKR3 drives atherosclerosis by promoting immune cell adhesion to vascular endothelium
Emiel van der Vorst
May 24, 2022 | 90th EAS Congress 2022, Endothelial cell biology in atherosclerosis | #
Acetate reverses the gut microbiota metabolite phenylacetyl glutamine (PAG)-induced endothelial senescence by epigenetic and SASP modulation
Seyed Soheil Saeedi Saravi
May 24, 2022 | 90th EAS Congress 2022, Endothelial cell biology in atherosclerosis | #
Acute coronary syndrome revisited: New mechanisms, new therapies
Filippo Crea
May 24, 2022 | 90th EAS Congress 2022, Advanced clinical seminar: Changing face of atherosclerosis | #
Clonal Hematopoiesis and Atherosclerosis
Peter Libby
May 24, 2022 | 90th EAS Congress 2022, Advanced clinical seminar: Changing face of atherosclerosis | #
Acute coronary syndrome revisited: New mechanisms, new therapies
Filippo Crea
May 24, 2022 | 90th EAS Congress 2022, Advanced clinical seminar: Changing face of atherosclerosis | #
Clonal Hematopoiesis and Atherosclerosis
Peter Libby
May 24, 2022 | 90th EAS Congress 2022, Advanced clinical seminar: Changing face of atherosclerosis | #
Communication and management of ASCVD through new technologies
Julie Redfern
May 24, 2022 | 90th EAS Congress 2022, Advanced clinical seminar: Changing face of atherosclerosis | #
The global Registry
Antonio J. Vallejo-Vaz
May 24, 2022 | 90th EAS Congress 2022, WHF Session 2: Global FH | #
How patient empowerment can improve outcomes
Jasmine Patel
May 24, 2022 | 90th EAS Congress 2022, WHF Session 2: Global FH | #
FH Screening- how to do universal screening and why
Urh Groselj
May 24, 2022 | FH Week 2022, 90th EAS Congress 2022, WHF Session 2: Global FH | #
Changing policy at EU level
Magdalena Daccord
May 24, 2022 | 90th EAS Congress 2022, WHF Session 2: Global FH | #
WHF Session 2: Global FH – Panel discussion
Kausik Ray, Magdalena Daccord, Antonio J. Vallejo-Vaz, Jasmine Patel, Urh Groselj
May 24, 2022 | FH Week 2022, 90th EAS Congress 2022, WHF Session 2: Global FH | #
Does the location of ectopic fat matter for CVD risk
Michael Roden
May 24, 2022 | 90th EAS Congress 2022, Cardiometabolic Risk and Ectopic Fat | #
Diabetes care: Changing the focus from treat to target to treat to benefit
Giorgio Sesti
May 24, 2022 | 90th EAS Congress 2022, Cardiometabolic Risk and Ectopic Fat | #
Genetic risk of fatty liver disease and mortality in the general population
Helene Gellert-Kristensen
May 24, 2022 | 90th EAS Congress 2022, Cardiometabolic Risk and Ectopic Fat | #
Impact of non-alcoholic fatty liver disease on coronary artery disease: a mendelian randomization study
Émilie Gobeil
May 24, 2022 | 90th EAS Congress 2022, Cardiometabolic Risk and Ectopic Fat | #
Low production of 12_-hydroxylated bile acids prevents hepatic steatosis in mice with a human-like bile acid pool by reducing fat absorption
Anna Palmiotti
May 24, 2022 | 90th EAS Congress 2022, Cardiometabolic Risk and Ectopic Fat | #
De novo lipogenesis mediates beneficial effects of isoenergetic dietary interventions on fatty liver: insights from the medea randomized clinical trial
Giuseppe Della Pepa
May 24, 2022 | 90th EAS Congress 2022, Cardiometabolic Risk and Ectopic Fat | #
High antibody titers against apolipoprotein-A1 in NAFLD: a possible link between fatty liver disease and CVD?
Sabrina Pagano
May 24, 2022 | 90th EAS Congress 2022, Cardiometabolic Risk and Ectopic Fat | #
Cardiometabolic Risk and Ectopic Fat – Discussion and Q&A
Alberto Mello e Silva, Philippe Moulin, Michael Roden, Giorgio Sesti, Helene Gellert-Kristensen, Émilie Gobeil, Anna Palmiotti, Giuseppe Della Pepa, Sabrina Pagano
May 24, 2022 | 90th EAS Congress 2022, Cardiometabolic Risk and Ectopic Fat | #
Pad An Underestimated Risk Factor For Cvd
Jill Belch
May 24, 2022 | 90th EAS Congress 2022, EAS Consensus activities | #
Antithrombotic therapy in PAD
Iris Baumgartner
May 24, 2022 | 90th EAS Congress 2022, EAS Consensus activities | #
Lipoprotein(a) – on the way to a consensus
Florian Kronenberg
May 24, 2022 | 90th EAS Congress 2022, EAS Consensus activities | #
Non-alcoholic steatohepatitis is reflected by levels of systemic soluble TREM2 and limited by the recruitment of TREM2-positive macrophages to areas of lipid-induced tissue damage
Florentina Porsch
May 24, 2022 | 90th EAS Congress 2022, Free Communication 2 - New insights into lipoprotein metabolism and vascular biology and atherosclerosis | #
B cell-specific GPR55 deficiency promotes atherosclerosis
Raquel Guillamat-Prats
May 24, 2022 | 90th EAS Congress 2022, Free Communication 2 - New insights into lipoprotein metabolism and vascular biology and atherosclerosis | #
WNT5A promotes lysosomal cholesterol egress and protects against atherosclerosis
Philippe Boucher
May 24, 2022 | 90th EAS Congress 2022, Free Communication 2 - New insights into lipoprotein metabolism and vascular biology and atherosclerosis | #
Transforming growth factor-_1 deficiency in B cells decrease atherosclerosis in APOE-/- mice
Daniela Baptista
May 24, 2022 | 90th EAS Congress 2022, Free Communication 2 - New insights into lipoprotein metabolism and vascular biology and atherosclerosis | #
Boosting cholesterol efflux from foam cells by sequential administration of RHDL to deliver microRNA and to remove cholesterol in a triple-cell two-dimensional atherosclerosis model
Shifa Jebari Benslaiman
May 24, 2022 | 90th EAS Congress 2022, Free Communication 2 - New insights into lipoprotein metabolism and vascular biology and atherosclerosis | #
Multi-omic profiling of LXR activation identifies SLPG as a sterol-inducible lysoplasmalogenase in macrophages
Suzanne van Wuow
May 24, 2022 | 90th EAS Congress 2022, Free Communication 2 - New insights into lipoprotein metabolism and vascular biology and atherosclerosis | #
EAS Advanced Course in Rare Lipid Disorders – Spanish Lipid Association
Luis Masana, Daiana Ibarretxe, Sergio Martínez Hervas, José López Miranda, Pedro Valdivielso, Francisco Blanca Vaca, Silvia Meavilla Oliva, Javier Adolfo de las Heras Montero
April 28, 2022 | Webinars on-demand | #
LCN Workshop on Clinical Lipidology – Germany
Ulrich Laufs, Winfried März, Wolfgang Koenig, Martin Merkel, Ioanna Gouni-Berthold, Ulrike Schatz
April 7, 2022 | Webinars on-demand | #
Network Medicine and Drug Repurposing in Cardiovascular Disease
Joseph Loscalzo, Harald HHW Schmidt, Péter Ferdinandy, Paolo Parini
April 6, 2022 | Webinars on-demand | #
Contribution of polygenic scores in the diagnosis of common dyslipidemia
Philippe Moulin, Maurizio Averna, Jacqueline Dron, Laurens F Rens Reeskamp
March 17, 2022 | Webinars on-demand | #
Proteomics in cardiovascular disease
Jemma Hopewell, Manuel Mayr, Thorsten Kessler, Christoph Binder
February 9, 2022 | Webinars on-demand | #
Will PROMINENT be really prominent?
Aruna Pradhan
89th EAS Congress 2021 | #
Who will benefit most from PCSK9i?
Erik Stroes
89th EAS Congress 2021 | #
Which patient needs the PCSK9 inhibitors most?
J. Wouter Jukema
89th EAS Congress 2021 | #
Triglyceride Metabolism in the Liver
David E. Cohen
89th EAS Congress 2021 | #
Triglyceride metabolism and its clinical implications
Chris Packard
89th EAS Congress 2021 | #
The Mediterranean diet, its components, and cardiovascular disease
Miguel Martinez-Gonzalez
89th EAS Congress 2021 | #
The role of smooth muscle cells in plaque stability
Helle Jorgensen
89th EAS Congress 2021 | #
The resistant patients with HoFH – novel approaches to reducing LDL cholesterol
Robert Rosenson
FH Week 2022, 89th EAS Congress 2021 | #
The Interface of Immune and Metabolic Responses in Atherosclerosis
Esther Lutgens
89th EAS Congress 2021 | #
The Impact of Diet on Gut Microbiota in Health and Disease
Wendy Garrett
89th EAS Congress 2021 | #
The evolving story of Omega-3 trials and reduction of CVD risk
Jane Armitage
89th EAS Congress 2021 | #
SPPARM alpha agonist as for Nutrient and Energy Metabolism – Mechanisms and Therapeutic Opportunities
Jean-Charles Fruchart
89th EAS Congress 2021 | #
Seeing is believing
Matthew J. Budoff
89th EAS Congress 2021 | #
Science versus reality: Real life Clinical Cases
Alberto Zambon
89th EAS Congress 2021 | #
Role apo apoC-III in the metabolism of triglyceride rich lipoproteins
Marja-Riitta Taskinen
89th EAS Congress 2021 | #
Primary prevention in ageing societies
Martin Mortenson
89th EAS Congress 2021 | #
Predictors of residual risk from Lp(a) to apo B
Brian Ference
89th EAS Congress 2021 | #
Polypill or polyfunctional pill in CV prevention?
Isabella Sudano
89th EAS Congress 2021 | #
Polygenic and clinical risk scores and their impact on age of onset and prediction of cardiovascular diseases
Samuli Ripatti
89th EAS Congress 2021 | #
Platelet activation and inhibition in dyslipidemias
Carlo Patrono
89th EAS Congress 2021 | #
PCSK9i: What have we learnt, what else needs clarification?
Gilles Lambert
89th EAS Congress 2021 | #
PCSK9 deficiency and heart metabolism
Giuseppe Danilo Norata
89th EAS Congress 2021 | #
Novel insight into the genetics of hypetriglyceridemia
Jacqueline Dron
89th EAS Congress 2021 | #
New Phenotypes for Stratification and Modeling of Atherosclerosis
Gerard Pasterkamp
89th EAS Congress 2021 | #
NAFLD: a multisystem disease
Christopher D Byrne
89th EAS Congress 2021 | #
Modern dyslipidemia management in ACS
Ulf Landmesser
89th EAS Congress 2021 | #
Metabolism and atherogenicity of apoB-containing lipoproteins
Jan Borén
89th EAS Congress 2021 | #
Mechanisms of acute coronary syndromes
Filippo Crea
89th EAS Congress 2021 | #
Management of severe hypertriglyceridemia
Arca Marcello
89th EAS Congress 2021 | #
Macrophage immunometabolism in atherosclerosis
Ira Tabas
89th EAS Congress 2021 | #
Lymphatics in the Regulation of Intestinal Lipid Mobilization
Gary Lewis
89th EAS Congress 2021 | #
Lymphatic System in Cardiovascular Medicine
Kari Alitalo
89th EAS Congress 2021 | #
Lifestyle and prevention: how do we define success?
Benoit Arsenault
89th EAS Congress 2021 | #
Is it worth targeting inflammation?
Ulf Landmesser
89th EAS Congress 2021 | #
Is gut microbiota a risk factor for cardiovascular disease?
Christoph Reinhardt
89th EAS Congress 2021 | #
Intensive Lipid lowering- moving beyond statins alone
Luis Masana
89th EAS Congress 2021 | #
Genetic factors underlying aortic valve calcification
Johanna Kuusisto
89th EAS Congress 2021 | #
From genetic discovery to clinical interventions to combat atherosclerosis
Mark Daly
89th EAS Congress 2021 | #
Calcium scoring in women: Is it different?
Laxmi Mehta
89th EAS Congress 2021 | #
Benefits of long-chain omega-3 fatty acids : from bench to bedside
Philip Calder
89th EAS Congress 2021 | #
Atherosclerosis management: will the future look smarter?
Thomas Luscher
89th EAS Congress 2021 | #
Atherosclerosis affecting fat: What can we learn by imaging perivascular adipose tissue?
Charalambos Antoniades
89th EAS Congress 2021 | #
Are all omegas 3 made equal or Omega 3s – All for one and one for all?
Preston Mason
89th EAS Congress 2021 | #
Aortic valve calcification: The role of lipoprotein (a)
Florian Kronenberg
89th EAS Congress 2021 | #
Anitschkow Lecture
Rory Collins
89th EAS Congress 2021 | #
ANGPTLs as a novel targets to reduce CVD risk
Sander Kersten
89th EAS Congress 2021 | #
ANGLT3 biology and genetics
Stefano Romeo
89th EAS Congress 2021 | #
A tale of two trials
Ulrich Laufs
89th EAS Congress 2021 | #
Why and in whom is combination needed?
Luis Masana
88th EAS Congress 2020 | #
When do we need add on therapies to statin?
Ulrich Laufs
88th EAS Congress 2020 | #